5326122026-07-012026-09-305326122026-09-305326122026-03-315326122026-04-012026-09-305326122026-07-012026-09-30in-capmkt:OtherExpenses1Member5326122026-07-012026-09-30in-capmkt:OtherExpenses2Member5326122026-04-012026-09-30in-capmkt:OtherExpenses1Member5326122026-04-012026-09-30in-capmkt:OtherExpenses2Member5326122026-09-30OtherNoncurrentFinancialAssetsDomain15326122026-09-30OtherNoncurrentAssetsDomain15326122026-09-30OtherCurrentFinancialAssetsDomain15326122026-09-30OtherCurrentAssetsDomain15326122026-09-30OtherCurrentAssetsDomain25326122026-09-30OtherNoncurrentFinancialLiabilitiesDomain15326122026-09-30OtherNoncurrentFinancialLiabilitiesDomain25326122026-09-30OtherNoncurrentLiabilitiesDomain15326122026-09-30OtherCurrentFinancialLiabilitiesDomain15326122026-09-30OtherCurrentFinancialLiabilitiesDomain25326122026-09-30OtherCurrentLiabilitiesDomain15326122026-07-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15326122026-04-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15326122026-07-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15326122026-04-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares532612INDOCONOTLISTEDINE873D01024INDOCO REMEDIES LIMITEDMain BoardEquity2026-04-012027-03-312026-10-272026-10-14INRLakhsQuarterlySecond quarterSingle segmentPharmaceuticals2026-10-2711:20:002026-10-2712:40:00trueCash Flow IndirectNot applicable2026-07-012026-09-30UnauditedConsolidated52017000001970000052214000001276300000557900000-35800000105110000026910000034440000018879000005350900000-12950000037140000024190000086100000-389000004720000001947000000000194700000-3400000191300000183800000109000001804000001090000018460000022.112.11002.112.11 <br /> 1. The unaudited Consolidated Results for the Quarter and Half Year ended 30th September,2026, have been reviewed by the Audit committee and approved by the Board of Directors of the Company at its meeting held on 27th October, 2026. The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Consolidated Financial Results. <br /> <br /> 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. <br /> <br /> 3. The company has only one primary reportable segment of activity, namely, Pharmaceuticals. <br /> <br /> 4. Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: <br /> <br /> (Rs. in Lakhs) <br /> Net Sales Qtr ended Qtr ended Qtr ended Half year ended Half year ended Year ended <br /> & Income 30-09-2026 30-06-2026 30-09-2025 30-09-2026 30-09-2025 31-03-2026 <br /> from Operations (Unaudited) ( Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) <br /> <br /> India 33,577 31,177 30,371 64,754 58,153 1,12,412 <br /> Outside India 17,115 15,445 16,812 32,560 32,117 66,882 ------------------------------------------------------------------------------------------------------------------------------------------- <br /> Total 50,692 46,622 47,183 97,314 90,270 1,79,294 <br /> ===================================================================== <br /> <br /> 5. The Consolidated Financial Results includes the results of the following companies. <br /> ----------------------------------------------------------------------------------------------------------------------------- <br /> Name of the Company % of shareholding Consolidated as <br /> ------------------------------------------------------------------------------------------------------------------------------ <br /> XTEND INDUSTRIAL DESIGNERS 100.00 SUBSIDIARY <br /> & ENGINEERS PVT LTD <br /> INDOCO REMEDIES CZECH SRO 100.00 SUBSIDIARY <br /> INDOCO REMEDIES UK LTD 100.00 SUBSIDIARY <br /> WARREN REMEDIES PVT LTD 100.00 SUBSIDIARY <br /> WARREN LIFESCIENCES PRIVATE LIMITED 100.00 SUBSIDIARY <br /> FPP HOLDING COMPANY, LLC 85.00 SUBSIDIARY <br /> -------------------------------------------------------------------------------------------------------------------------- <br /> <br /> 6. The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 30th September, 2026 <br /> <br /> 7.(*) Exceptional items during the quarter includes : <br /> (a) Gain on sale of the Company's property situated at Andheri (East), Mumbai, amounting to Rs 3,663 Lakhs. The property was classified as held for sale as at 31 March 2026 in accordance with Ind AS 105. <br /> (b) Consideration received Rs. 51 lakhs for grant to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company, <br /> <br /> 8. Warren Lifesciences Private Limited was incorporated on 26th September 2026 and is considered a wholly- owned subsidiary of Indoco Remedies Limited in accordance with Ind AS 1102026-04-012026-09-30UnauditedConsolidated98767000004160000099183000002322000000956900000999000002065200000552000000689700000355820000010243900000-32560000013448000001019200000192000000-22000000170000000084920000000008492000003600000852800000833800000154000008374000001540000018460000029.219.2009.219.2Research & Development Expense209800000Other Expenses1678100000Research & Development Expense395300000Other Expenses31629000009294000000267700000328000002152000002158400000696600000533000002620000021250000029200000091440000013871100000396650000010110000053755000003476000007650000046800000646000006012100000227770000012256300000261274000001846000001003080000010215400000-56200000101592000005137500000671800000580930000034230000018900000749000006245400000462350000088250000019084000002790900000129390000087083000004915000004535000006950000097228000001596820000026127400000Other Financial Assets212500000Other non-current assets914400000Other current financial assets64600000Other current assets2232500000Assets Classified as held for Sale45200000Other Financial Liabilities18400000Lease Liabilities653400000Other non-current liabilities74900000Other current financial liabilities1116400000Lease Liabilities177500000Other current liabilities49150000059370000085600000-5537000000-1286000001420000014700000-51000000-2825000000-9110000006897000000-15300000-265000004410000036670000013800000022200000370000000030600000160000007334000001752600000000-93100000018457000000001398000000000236100000604900000000000000000000000222000000-5900000-492300000000000007467000001319100000839000001860000059000000000-126490000088500000088500000259300000347800000Items that will not be reclassified to profit and loss-6200000-6200000Items that will not be reclassified to profit and loss-12300000-12300000-1500000-3100000Items that may be reclassified to profit or loss13000001300000Items that may be reclassified to profit or loss13100000131000000300000-34000003600000